Conference Coverage

Tailored messaging needed to get cancer screening back on track


 

Building trust

All the panelists agreed that building trust with the public will be key to getting cancer care back on track.

“I don’t think anyone trusts the healthcare community right now, but we already had this baseline distrust of healthcare among many minority communities, and now with COVID-19, the African American community in particular is seeing people go into the hospital and never come back,” said Richardson.

For Warner, the onus really falls on healthcare institutions. “We have to be proactive and not leave the burden of deciding when and how to return to care up to patients,” she said.

“What we need to focus on as much as possible is to get people to realize it is safe to come see the doctor,” said Johns Hopkins oncologist Brawley. “We have to make it safe for them to come see us, and then we have to convince them it is safe to come see us.”

Venturing out to her mammography appointment in early June, Richardson said she felt safe. “Everything was just the way it was supposed to be, everyone was masked, everyone was washing their hands,” she said.

Yet, by mid-June she had contracted COVID-19. “I don’t know where I got it,” she said. “No matter how careful you are, understand that if you’re in a total red spot, as I am, you can just get it.”

This article first appeared on Medscape.com.

Pages

Recommended Reading

Androgens may explain male vulnerability to COVID-19
Covid ICYMI
Active cancer increases death risk in patients with COVID-19
Covid ICYMI
‘A good and peaceful death’: Cancer hospice during the pandemic
Covid ICYMI
Can an app guide cancer treatment decisions during the pandemic?
Covid ICYMI
More than 10,000 excess cancer deaths because of COVID-19 delays
Covid ICYMI
CCC19, other registries help define COVID/cancer landscape
Covid ICYMI
Higher death rate seen in cancer patients with nosocomial COVID-19
Covid ICYMI
OK to treat many cancer patients despite pandemic, says ESMO
Covid ICYMI
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
Covid ICYMI
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
Covid ICYMI